Order Article Reprints

Chaves OA, Sacramento CQ, Ferreira AC, Mattos M, Fintelman-Rodrigues N, Temerozo JR, Vazquez L, Pinto DP, da Silveira GPE, da Fonseca LB, et al. Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M^pro, Impairing Variants Replication In Vitro and In Vivo. Pharmaceuticals. 2022; 15(1):21. https://doi.org/10.3390/ph15010021

Chaves, Otávio Augusto, Carolina Q. Sacramento, André C. Ferreira, Mayara Mattos, Natalia Fintelman-Rodrigues, Jairo R. Temerozo, Leonardo Vazquez, Douglas Pereira Pinto, Gabriel P. E. da Silveira, Laís Bastos da Fonseca, and et al. 2022. "Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M^pro, Impairing Variants Replication In Vitro and In Vivo" Pharmaceuticals 15, no. 1: 21. https://doi.org/10.3390/ph15010021

Chaves, O. A., Sacramento, C. Q., Ferreira, A. C., Mattos, M., Fintelman-Rodrigues, N., Temerozo, J. R., Vazquez, L., Pinto, D. P., da Silveira, G. P. E., da Fonseca, L. B., Pereira, H. M., Carlos, A. S., d’Avila, J. C., Viola, J. P. B., Monteiro, R. Q., Bozza, P. T., Castro-Faria-Neto, H. C., & Souza, T. M. L. (2022). Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M^pro, Impairing Variants Replication In Vitro and In Vivo. Pharmaceuticals, 15(1), 21. https://doi.org/10.3390/ph15010021